{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:03:59Z","timestamp":1787965439179,"version":"build-2784847793"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JIMD Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Hypophosphatasia (HPP) is an inherited metabolic disease caused by deficient tissue\u2010nonspecific alkaline phosphatase (ALP) activity and characterized by skeletal and nonskeletal symptoms, including muscle weakness and fatigue. We hypothesized that mitochondrial respiration is impaired in muscle in HPP, independent of skeletal manifestations, and that the second\u2010generation ALP enzyme replacement therapy (ERT) efzimfotase alfa improves respiration. Akp2GW\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice were used for this purpose. Body weight, bone mineralization, and survival were validated in Akp2GW\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice versus Akp2\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice, an established model of HPP. No significant differences were found, validating the Akp2GW\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    model. Respiratory outcomes were measured in skeletal muscle fiber bundles in age\u2010 and sex\u2010matched Akp2GW\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    and Akp2GW\n                    <jats:sup>+\/+<\/jats:sup>\n                    (wild\u2010type) mice; bone mineralization was assessed. Mean maximal respiration and mitochondrial spare respiratory capacity (SRC) in vehicle\u2010treated Akp2GW\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice were 37% and 30% of values from wild\u2010type mice, respectively, independent of skeletal manifestations. Efzimfotase alfa treatment significantly improved maximal respiration in tissue from Akp2GW\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice by 147% versus vehicle (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0059) and improved SRC by 262% versus vehicle (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0008). Mean maximal respiration and SRC in tissue from efzimfotase alfa\u2010treated Akp2GW\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice were 92% and 107%, respectively, of tissue from wild\u2010type mice. Cellular ultrastructure of muscle biopsies from people with HPP showed atypical mitochondrial morphology, including branching cristae and dispersed matrix. In a mouse model of HPP, we show that the altered mitochondrial respiration in skeletal muscle is improved by ERT and that HPP is characterized by altered muscle mitochondrial morphology in humans. Together, these data suggest ERT could improve muscular symptoms in HPP.\n                  <\/jats:p>","DOI":"10.1002\/jmd2.70057","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:52:02Z","timestamp":1767189122000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efzimfotase Alfa Improves Respiratory Capacity in Muscle Tissue From a Mouse Model of\n                    <scp>HPP<\/scp>"],"prefix":"10.1002","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8219-3233","authenticated-orcid":false,"given":"Denise","family":"Devore","sequence":"first","affiliation":[{"name":"Pharmacology, Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1269-4650","authenticated-orcid":false,"given":"Juan","family":"Ruanova","sequence":"additional","affiliation":[{"name":"In Vitro and In\u00a0Vivo Pharmacology, Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Voegtli","sequence":"additional","affiliation":[{"name":"Discovery Research, Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Dunn","sequence":"additional","affiliation":[{"name":"Clinical Development, Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Decker","sequence":"additional","affiliation":[{"name":"MeTa+ Global SciComm, Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-5990","authenticated-orcid":false,"given":"Maurizio","family":"Mazzantini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-4800","authenticated-orcid":false,"given":"Vincenzo","family":"De Tata","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery University of Pisa  Pisa Italy"},{"name":"C.I.M.E. Interdepartmental Center of Electron Microscopy University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9393","authenticated-orcid":false,"given":"Maria Concetta","family":"Scavuzzo","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-6594","authenticated-orcid":false,"given":"Francesco","family":"Conti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8017-0170","authenticated-orcid":false,"given":"Anna","family":"Petryk","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[{"name":"FirmoLab, F.I.R.M.O. Italian Foundation for the Research on Bone Diseases  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"2","key":"e_1_2_12_2_1","first-page":"380","article-title":"Hypophosphatasia","volume":"10","author":"Rockman\u2010Greenberg C.","year":"2013","journal-title":"Pediatric Endocrinology Reviews"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.33176\/aacb\u201019\u201000031"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116504"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010023\u201006844\u20101"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1530\/ec\u201022\u20100240"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010022\u201002393\u20108"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.07.006"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.12.011"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1138599"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.12.2015"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097\u20100177(199703)208:3<432::aid\u2010aja13>3.0.co;2\u20101"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.071213"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115905"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031140"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010018\u201035079\u2010y"},{"key":"e_1_2_12_17_1","volume-title":"Presented at: Annual Meeting of the American Society for Bone and Mineral Research","author":"Bertels J.","year":"2020"},{"key":"e_1_2_12_18_1","volume-title":"Strensiq [Package Insert]","author":"Alexion Pharmaceuticals","year":"2024"},{"key":"e_1_2_12_19_1","volume-title":"Strensiq [Summary of Product Characteristics]","author":"Alexion Europe SAS","year":"2020"},{"key":"e_1_2_12_20_1","unstructured":"\u201cReport on the Deliberation Results: Strensiq Subcutaneous Injection \u201d2015 https:\/\/www.pmda.go.jp\/english\/review\u2010services\/reviews\/approved\u2010information\/drugs\/0001.html#select19."},{"key":"e_1_2_12_21_1","unstructured":"Alexion Pharmaceuticals \u201cStrensiq (Asfotase Alfa) Receives Marketing Approval in Japan for Treatment of Patients With Hypophosphatasia (HPP) [Press Release] \u201d2015 https:\/\/www.fiercepharma.com\/pharma\u2010asia\/strensiq%C2%AE\u2010asfotase\u2010alfa\u2010receives\u2010marketing\u2010approval\u2010japan\u2010for\u2010treatment\u2010of\u2010patients."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106173"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85971"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010024\u201003048\u20106"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10395"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116856"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010018\u20104552\u20103"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10052"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100643"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010023\u201006943\u2010z"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae128"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000767R"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj20110162"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2089"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscatal.9b03907"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116007"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.22.010305.104538"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102164"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.735678"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2017.1.20160542"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDS.S112119"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2015.11.031"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2010.12.015"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2012.04.008"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00457a001"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.1.130"}],"container-title":["JIMD Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmd2.70057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmd2.70057","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmd2.70057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:01:08Z","timestamp":1769601668000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmd2.70057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/jmd2.70057"],"URL":"https:\/\/doi.org\/10.1002\/jmd2.70057","archive":["Portico"],"relation":{},"ISSN":["2192-8312","2192-8312"],"issn-type":[{"value":"2192-8312","type":"print"},{"value":"2192-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70057"}}